44 results
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
GBS a beachhead for mechanistically-related neuro and Majority of patients treated in major metro areas 2 and large community hospitals autoimmune … Summary of Key Results A profound moment for the GBS community – first targeted therapy to demonstrate positive outcomes Phase 3 Met Primary Endpoint
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
for patients and the healthcare community. ANX005 also provided an early reduction in the prespecified analysis of serum levels of neurofilament light … ).
“These data represent an important moment for the GBS community and Annexon,” said Douglas Love, president and chief executive officer of Annexon
8-K
EX-99.1
6ax2b6
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.2
h46aaxl
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm